Esperion Therapeutics | ESPR - Equity Capital And Reserves


Esperion Therapeutics reported $-301.96M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amarin USD 449.41M 9.87M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cipla INR 329.19B 16.3B Sep/2025
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -826.57M 166.94M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Geron USD 225.87M 22.83M Dec/2025
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025